Use of proteasome inhibitors to examine processing of antigens for major histocompatibility complex class I presentation.
Antón
L C
LC
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Bennink
J R
JR
Yewdell
J W
JW
D000818:Animals; D017951:Antigen Presentation; D002460:Cell Line; D002462:Cell Membrane / Q000276:immunology; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D005805:Genes, MHC Class I / Q000187:drug effects; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis* / Q000737:chemistry / Q000235:genetics*; D006801:Humans; D007202:Indicators and Reagents; D009097:Multienzyme Complexes / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex; D011487:Protein Conformation; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000737:chemistry; D014162:Transfection; D014407:Tumor Cells, Cultured
D015853:Cysteine Proteinase Inhibitors; D015395:Histocompatibility Antigens Class I; D007202:Indicators and Reagents; D009097:Multienzyme Complexes; D011993:Recombinant Fusion Proteins; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex